| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 82.03 mm | 82.03 mm | 82.03 mm | 82.03 mm | 82.03 mm | 82.03 mm |
| Cash burn (monthly) | 3.84 mm | (no burn) | (no burn) | 663.92 k | 3.84 mm | 3.06 mm |
| Cash used (since last report) | 19.46 mm | n/a | n/a | 3.36 mm | 19.46 mm | 15.52 mm |
| Cash remaining | 62.57 mm | n/a | n/a | 78.67 mm | 62.57 mm | 66.51 mm |
| Runway (months of cash) | 16.3 | n/a | n/a | 118.5 | 16.3 | 21.7 |
| 13F holders | Current |
|---|---|
| Total holders | 20 |
| Opened positions | 7 |
| Closed positions | 10 |
| Increased positions | 1 |
| Reduced positions | 1 |
| 13F shares | Current |
|---|---|
| Total value | 652.38 mm |
| Total shares | 3.22 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Ikarian Capital | 970.36 k | $9.35 mm |
| Biotechnology Value Fund L P | 967.30 k | $8.90 mm |
| Ra Capital Management | 967.30 k | $8.90 mm |
| Patrick J Crutcher | 110.85 k | $1.02 mm |
| Allostery Investments | 78.26 k | $1.25 mm |
| Emerald Bioventures | 58.35 k | $277.00 k |
| Affinity Asset Advisors | 45.00 k | $425.70 mm |
| Vanguard | 10.37 k | $98.08 mm |
| Geode Capital Management | 10.11 k | $95.65 mm |
| BlackRock | 329.00 | $3.13 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 28 Jan 25 | Mittie Doyle | Stock Option Common Stock | Grant | Acquire A | No | No | 8.04 | 155,000 | 1.25 mm | 155,000 |
| 28 Jan 25 | Neil Garry Arthur | Stock Option Common Stock | Grant | Acquire A | No | No | 8.04 | 411,000 | 3.30 mm | 411,000 |
| 28 Jan 25 | Christopher Ryan Sullivan | Stock Option Common Stock | Grant | Acquire A | No | No | 8.04 | 163,000 | 1.31 mm | 163,000 |
| 28 Jan 25 | Paul Varki | Stock Option Common Stock | Grant | Acquire A | No | No | 8.04 | 100,000 | 804.00 k | 100,000 |
| 1 Jan 25 | Jennifer Riley | Stock Option Common Stock | Grant | Acquire A | No | No | 7.43 | 150,000 | 1.11 mm | 150,000 |
